CN109089419B - April的抗体分子及其应用 - Google Patents

April的抗体分子及其应用 Download PDF

Info

Publication number
CN109089419B
CN109089419B CN201680079727.0A CN201680079727A CN109089419B CN 109089419 B CN109089419 B CN 109089419B CN 201680079727 A CN201680079727 A CN 201680079727A CN 109089419 B CN109089419 B CN 109089419B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
monoclonal antibody
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680079727.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109089419A (zh
Inventor
J·R·麦特
Z·H·施莱弗
K·维斯瓦纳坦
A·M·沃尔拉科特
H·阿达瑞-霍尔
B·拉马克里施南
G·巴布科克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistra Corp
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Priority to CN202410173854.3A priority Critical patent/CN118420760A/zh
Priority to CN202410173851.XA priority patent/CN118027201A/zh
Publication of CN109089419A publication Critical patent/CN109089419A/zh
Application granted granted Critical
Publication of CN109089419B publication Critical patent/CN109089419B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CN201680079727.0A 2015-11-25 2016-11-23 April的抗体分子及其应用 Active CN109089419B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410173854.3A CN118420760A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用
CN202410173851.XA CN118027201A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562259897P 2015-11-25 2015-11-25
US62/259,897 2015-11-25
US201662313684P 2016-03-25 2016-03-25
US62/313,684 2016-03-25
US201662399087P 2016-09-23 2016-09-23
US62/399,087 2016-09-23
US201662422848P 2016-11-16 2016-11-16
US62/422,848 2016-11-16
PCT/US2016/063518 WO2017091683A1 (en) 2015-11-25 2016-11-23 Antibody molecules to april and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410173854.3A Division CN118420760A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用
CN202410173851.XA Division CN118027201A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用

Publications (2)

Publication Number Publication Date
CN109089419A CN109089419A (zh) 2018-12-25
CN109089419B true CN109089419B (zh) 2024-03-01

Family

ID=57543212

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680079727.0A Active CN109089419B (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用
CN202410173851.XA Pending CN118027201A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用
CN202410173854.3A Pending CN118420760A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410173851.XA Pending CN118027201A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用
CN202410173854.3A Pending CN118420760A (zh) 2015-11-25 2016-11-23 April的抗体分子及其应用

Country Status (27)

Country Link
US (9) US20170145086A1 (https=)
EP (2) EP4285923A3 (https=)
JP (4) JP2019506363A (https=)
KR (2) KR102747820B1 (https=)
CN (3) CN109089419B (https=)
AU (2) AU2016361488B2 (https=)
CA (1) CA3006058A1 (https=)
CL (2) CL2018001372A1 (https=)
CO (1) CO2018006461A2 (https=)
DK (1) DK3380522T5 (https=)
ES (1) ES2970864T3 (https=)
FI (1) FI3380522T3 (https=)
HK (1) HK1254337A1 (https=)
HR (1) HRP20231578T1 (https=)
HU (1) HUE064791T2 (https=)
IL (2) IL259585B2 (https=)
LT (1) LT3380522T (https=)
MA (1) MA43308A (https=)
MX (2) MX2018006385A (https=)
MY (1) MY197345A (https=)
PL (1) PL3380522T3 (https=)
PT (1) PT3380522T (https=)
SA (1) SA518391659B1 (https=)
SG (1) SG11201804309PA (https=)
SI (1) SI3380522T1 (https=)
WO (1) WO2017091683A1 (https=)
ZA (1) ZA201803366B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210340266A1 (en) * 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
WO2020139834A1 (en) * 2018-12-24 2020-07-02 Visterra, Inc. Methods for identifying epitopes and paratopes
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
CN110522902B (zh) * 2019-09-25 2022-10-11 南京农业大学 一种用于建立慢性肾病模型的组合物及其应用
US20230052256A1 (en) * 2019-12-24 2023-02-16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
IL296358A (en) * 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
TW202216195A (zh) 2020-06-24 2022-05-01 美商威特拉公司 April抗體分子及其用途
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒
US20240228626A1 (en) * 2021-05-04 2024-07-11 Immunorizon Ltd. Anti-nkg2d antibodies and uses thereof
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
KR20240021179A (ko) * 2021-05-14 2024-02-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 폴리펩티드 및 사용 방법
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
US20240092921A1 (en) * 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
CN119930816A (zh) * 2023-11-02 2025-05-06 广东菲鹏制药股份有限公司 抗cd39人源化抗体或其抗原结合片段及其应用
WO2026067804A1 (zh) * 2024-09-30 2026-04-02 信立泰(成都)生物技术有限公司 一种抗april抗体或其抗原结合片段及用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
WO2007039489A1 (en) * 2005-09-26 2007-04-12 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
CN101678106A (zh) * 2007-03-27 2010-03-24 津莫吉尼蒂克斯公司 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合
WO2010100056A2 (en) * 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
CN103562225A (zh) * 2011-05-27 2014-02-05 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
SK3542000A3 (en) 1997-09-12 2000-08-14 Apotech R & D Sa Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
JP2004537290A (ja) * 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
CA2554526A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5314033B2 (ja) * 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
AU2009241442B2 (en) * 2008-05-01 2014-11-27 Zymogenetics, Inc. Levels of BLyS/ APRIL heterotrimers in serum and use in diagnostic methods
US20210340266A1 (en) 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
EP2488200A4 (en) * 2009-10-14 2013-06-12 Merck Sharp & Dohme APRIL ANTAGONISTS AND METHOD FOR THEIR USE
ES2751549T3 (es) * 2009-11-30 2020-04-01 Janssen Biotech Inc Mutantes de anticuerpos Fc con funciones efectoras ablacionadas
CN103249742B (zh) * 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
PL2718322T3 (pl) * 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
HK1219740A1 (zh) * 2013-03-15 2017-04-13 Biogen Ma Inc. 使用抗αVβ5抗体治疗和预防急性肾损伤
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
ES2884255T3 (es) * 2013-11-06 2021-12-10 Janssen Biotech Inc Anticuerpos anti-CCL17
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3245230B1 (en) 2015-01-15 2020-12-16 Université Grenoble Alpes Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
CN105390742A (zh) * 2015-12-31 2016-03-09 石家庄圣泰化工有限公司 高电压锂离子电池电解液及其制备方法及应用
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
TW202216195A (zh) 2020-06-24 2022-05-01 美商威特拉公司 April抗體分子及其用途
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
WO2007039489A1 (en) * 2005-09-26 2007-04-12 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
CN101678106A (zh) * 2007-03-27 2010-03-24 津莫吉尼蒂克斯公司 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合
WO2010100056A2 (en) * 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
CN103562225A (zh) * 2011-05-27 2014-02-05 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Development and characterization ofAPRILantagonisticmonoclonal antibodies for treatment of B-cell lymphomas";Marco Guadagnoli et al.;《BLOOD》;20110623;第117卷(第25期);第6856-6865页 *
"Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) inMurine IgA Nephropathy";Yang Gyun Kim et al.;《PLOS ONE》;20150908;第10卷(第9期);第1-13页 *
"Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse";Bertrand Huard et al.;《PLOS ONE》;20120215;第7卷(第2期);第1-8页 *
"Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL";Catarina Osório et al.;《Molecular and Cellular Neuroscience》;20140118;第59卷;第30-32页 *
"抗sAPRIL抗体的制备及细胞增殖抑制功能分析";杜本军 等;《中国实验血液学杂志》;20111231;第19卷(第4期);第1019-1022页 *

Also Published As

Publication number Publication date
KR102747820B1 (ko) 2024-12-27
ZA201803366B (en) 2025-09-25
SA518391659B1 (ar) 2022-12-13
JP7029018B2 (ja) 2022-03-02
EP3380522A1 (en) 2018-10-03
MX2018006385A (es) 2019-09-11
JP2024073611A (ja) 2024-05-29
US20190092851A1 (en) 2019-03-28
CL2018001372A1 (es) 2018-11-23
EP4285923A3 (en) 2024-03-06
KR20180091849A (ko) 2018-08-16
DK3380522T5 (da) 2024-09-30
JP2022068288A (ja) 2022-05-09
US20200331995A1 (en) 2020-10-22
US10385123B2 (en) 2019-08-20
US10968270B2 (en) 2021-04-06
CN109089419A (zh) 2018-12-25
CN118420760A (zh) 2024-08-02
CA3006058A1 (en) 2017-06-01
IL259585B2 (en) 2024-11-01
US20200317770A1 (en) 2020-10-08
NZ782617A (en) 2025-06-27
MA43308A (fr) 2018-10-03
PT3380522T (pt) 2024-02-14
AU2023201698A1 (en) 2023-04-20
IL259585A (en) 2018-07-31
AU2016361488B2 (en) 2022-12-22
ES2970864T3 (es) 2024-05-31
EP4285923A2 (en) 2023-12-06
US20210032324A1 (en) 2021-02-04
DK3380522T3 (da) 2024-01-22
IL313508A (en) 2024-08-01
AU2016361488A1 (en) 2018-06-14
MX2024010175A (es) 2024-08-27
SI3380522T1 (sl) 2024-02-29
WO2017091683A1 (en) 2017-06-01
KR20250008787A (ko) 2025-01-15
LT3380522T (lt) 2024-02-26
NZ742879A (en) 2025-06-27
US20170145086A1 (en) 2017-05-25
JP2021184740A (ja) 2021-12-09
CN118027201A (zh) 2024-05-14
WO2017091683A8 (en) 2022-12-15
IL259585B1 (en) 2024-07-01
MY197345A (en) 2023-06-14
US10954296B2 (en) 2021-03-23
HUE064791T2 (hu) 2024-04-28
HK1254337A1 (zh) 2019-07-19
PL3380522T3 (pl) 2024-03-25
CL2024000276A1 (es) 2024-08-30
FI3380522T3 (fi) 2024-01-16
US20200299376A1 (en) 2020-09-24
US20190330326A1 (en) 2019-10-31
CO2018006461A2 (es) 2018-08-31
HRP20231578T1 (hr) 2024-03-15
JP2019506363A (ja) 2019-03-07
EP3380522B1 (en) 2023-11-08
US20220235124A1 (en) 2022-07-28
BR112018010673A2 (pt) 2018-11-13
RU2018122452A3 (https=) 2020-05-13
NZ782606A (en) 2025-06-27
US10981982B2 (en) 2021-04-20
RU2018122452A (ru) 2019-12-25
US20250066464A1 (en) 2025-02-27
US12091451B2 (en) 2024-09-17
SG11201804309PA (en) 2018-06-28
US11136385B2 (en) 2021-10-05
BR112018010673A8 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
CN109089419B (zh) April的抗体分子及其应用
US20240150488A1 (en) Antibody Molecules to C5AR1 and Uses Thereof
CN119730874A (zh) 针对april的抗体分子及其用途
US20210340266A1 (en) Antibody molecules to april and uses thereof
TW202216195A (zh) April抗體分子及其用途
CN116670168A (zh) 针对april的抗体分子及其用途
RU2793755C2 (ru) Молекулы антител против april и их применения
HK40114871A (zh) April的抗体分子及其应用
HK40110880A (zh) April的抗体分子及其应用
HK40103484A (en) Antibody molecules to april and uses thereof
BR112018010673B1 (pt) Moléculas de anticorpo para april, composição, uso das mesmas, molécula de ácido nucléico, vetor, kit e método de detecção de uma molécula de april

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Massachusetts, USA

Patentee after: Wistra Corp.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: VISTERRA, Inc.

Country or region before: U.S.A.